Lista de obras - Violeta Serra - Dominio Público Uruguay

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds

artículo científico publicado en 2016

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

artículo científico publicado en 2018

A decade of clinical development of PARP inhibitors in perspective

scientific article published on 01 September 2019

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

artículo científico publicado en 2011

Accelerated telomere shortening in Fanconi anemia fibroblasts--a longitudinal study

artículo científico publicado en 2001

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation

artículo científico publicado en 2018

Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs

artículo científico publicado en 2006

Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer

artículo científico publicado en 2011

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

scientific article published on 11 December 2019

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1

artículo científico publicado en 2016

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

artículo científico publicado en 2016

Cancer network activity associated with therapeutic response and synergism

artículo científico publicado en 2016

Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity

artículo científico publicado en 2019

Clinical consequences of BRCA2 hypomorphism

publication published on 09 September 2021

Clinical impact of aortic regurgitation after transcatheter aortic valve replacement: insights into the degree and acuteness of presentation

artículo científico publicado en 2014

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

artículo científico publicado en 2013

Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.

artículo científico publicado en 2018

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

scientific article published on 07 January 2021

Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?

artículo científico publicado en 2019

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

artículo científico publicado en 2011

Development of PI3K inhibitors: lessons learned from early clinical trials

artículo científico

Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs

artículo científico publicado en 2019

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy

artículo científico publicado en 2012

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer

artículo científico publicado en 2016

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

artículo científico publicado en 2014

Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.

artículo científico publicado en 2013

Extracellular superoxide dismutase is a major antioxidant in human fibroblasts and slows telomere shortening

artículo científico publicado en 2002

Functional transcriptomics: an experimental basis for understanding the systems biology for cancer cells.

artículo científico publicado en 2007

Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity

artículo científico publicado en 2016

Genetic alterations in the PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts

scientific article published on 27 March 2020

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

artículo científico publicado en 2014

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review

artículo científico publicado en 2020

Human fibroblasts in vitro senesce with a donor-specific telomere length

artículo científico publicado en 2002

In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer

artículo científico publicado en 2018

Interrogating open issues in cancer medicine with patient-derived xenografts

artículo científico publicado en 2017

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

artículo científico publicado en 2017

Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response

artículo científico publicado en 2021

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.

artículo científico publicado en 2018

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.

scientific article published on 13 August 2015

MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer

artículo científico publicado en 2018

Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN

artículo científico publicado en 2015

Modulation of telomere protection by the PI3K/AKT pathway

artículo científico publicado en 2017

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy

scientific article published on 03 May 2019

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

scientific article published on 21 September 2018

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

artículo científico publicado en 2008

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

scientific article published on 22 August 2012

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

artículo científico publicado en 2011

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

artículo científico publicado en 2015

PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

artículo científico publicado en 2016

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

artículo científico publicado en 2008

Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors

artículo científico

Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.

artículo científico publicado en 2005

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer.

artículo científico publicado en 2018

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

artículo científico publicado en 2013

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

artículo científico publicado en 2014

Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

artículo científico publicado en 2017

Sensitizing HR-proficient cancers to PARP inhibitors

artículo científico publicado en 2017

Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells ⬇️

artículo científico publicado en 2018

Short telomeres in patients with vascular dementia: an indicator of low antioxidative capacity and a possible risk factor?

artículo científico publicado en 2000

Stratification and therapeutic potential of PML in metastatic breast cancer

artículo científico publicado en 2016

TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence

artículo científico publicado en 2018

Targeting a cell state common to triple-negative breast cancers

artículo científico publicado en 2015

Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells.

artículo científico publicado en 2018

Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?

artículo científico publicado en 2017

Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?

artículo científico publicado en 2018

Telomere length as a marker of oxidative stress in primary human fibroblast cultures

artículo científico publicado en 2000

Telomere shortening in human fibroblasts is not dependent on the size of the telomeric-3'-overhang

artículo científico publicado en 2004

The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models

scientific article published on 18 July 2019

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

artículo científico publicado en 2016

The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1.

artículo científico publicado en 2006

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

scientific article published on 13 May 2020

mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer

artículo científico publicado en 2013

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.

artículo científico publicado en 2017

p95HER2-T cell bispecific antibody for breast cancer treatment

artículo científico publicado en 2018

Lista de obras de Violeta Serra

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

A decade of clinical development of PARP inhibitors in perspective

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

Accelerated telomere shortening in Fanconi anemia fibroblasts--a longitudinal study

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation

Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs

Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

Cancer network activity associated with therapeutic response and synergism

Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity

Clinical consequences of BRCA2 hypomorphism

Clinical impact of aortic regurgitation after transcatheter aortic valve replacement: insights into the degree and acuteness of presentation

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

Development of PI3K inhibitors: lessons learned from early clinical trials

Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.

Extracellular superoxide dismutase is a major antioxidant in human fibroblasts and slows telomere shortening

Functional transcriptomics: an experimental basis for understanding the systems biology for cancer cells.

Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity

Genetic alterations in the PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review

Human fibroblasts in vitro senesce with a donor-specific telomere length

In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer

Interrogating open issues in cancer medicine with patient-derived xenografts

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.

MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer

Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN

Modulation of telomere protection by the PI3K/AKT pathway

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors

Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer.

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

Sensitizing HR-proficient cancers to PARP inhibitors

Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells ⬇️

Short telomeres in patients with vascular dementia: an indicator of low antioxidative capacity and a possible risk factor?

Stratification and therapeutic potential of PML in metastatic breast cancer

TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence

Targeting a cell state common to triple-negative breast cancers

Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells.

Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?

Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?

Telomere length as a marker of oxidative stress in primary human fibroblast cultures

Telomere shortening in human fibroblasts is not dependent on the size of the telomeric-3'-overhang

The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1.

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.

p95HER2-T cell bispecific antibody for breast cancer treatment